ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2023
Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Rising antimicrobial resistance in urinary tract infections in Türkiye: an urgent need for update on regional treatment strategies and for enhanced antimicrobial stewardship efforts.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Prevalence of and Factors Associated with Antibiotic Prescription in Gynecological Practices in Germany.Antibiotics (Basel, Switzerland) · 2026Article
- Fosfomycin Trometamol in the Management of Urinary Tract Infection: A Focus on Antimicrobial Susceptibility and Resistance.Infection and drug resistance · 2026Review
- [Prophylaxis of recurrent urinary tract infections by nitroxoline-real-world data of the ProNitrox study].Urologie (Heidelberg, Germany) · 2026Article
- Urinary tract infection in outpatients in Germany: a cross-sectional study of diagnostics and susceptibility testing in medical laboratories.BJGP open · 2025Article
- The incidence, clinical features and outcome of urinary tract infections in geriatric patients: A prospective longitudinal study.IJID regions · 2024Article
- Lessons from an 11-year retrospective cohort study ofIranian journal of microbiology · 2024Article
- Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.The Journal of antimicrobial chemotherapy · 2024Article
- A Five-Year Analysis of Antibiotic Resistance Trends among Bacteria Identified in Positive Urine Samples in a Tertiary Care Hospital from Bucharest, Romania.Antibiotics (Basel, Switzerland) · 2024Article
- Nitroxoline resistance is associated with significant fitness loss and diminishesMicrobiology spectrum · 2024Article
- Nitroxoline: treatment and prevention of urinary tract infections from the urologist's perspective.Central European journal of urology · 2024Review
- The Prevalence of Alert Pathogens and Microbial Resistance Mechanisms: A Three-Year Retrospective Study in a General Hospital in Poland.Pathogens (Basel, Switzerland) · 2023Article
- Nitrofuran Derivatives Cross-Resistance Evidence-UropathogenicJournal of clinical medicine · 2023Article
- Letter to the editor: Antimicrobial resistance data and treatment guidelines - challenges in the context of urine samples and mecillinam testing.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionEmpirical therapy for the treatment of urinary tract infections should be tailored to the current distribution and susceptibility of potential pathogens to ensure optimal treatment.AimWe aimed to provide an up-to-date overview of the epidemiology and susceptibility of Enterobacterales isolated from urine in Germany.MethodsWe retrospectively analysed antimicrobial susceptibility data from 201,152 urine specimens collected between January 2016 and June 2021 from in- and outpatients. Multiple logistic regression analysis was used to evaluate the association between year of investigation and antibiotic resistance, adjusted for age, sex and species subgroup. Subgroup analyses were performed for midstream urine samples obtained from (i) female outpatients aged 15 to 50 years, (ii) female outpatients older than 50 years and (iii) male outpatients.ResultsResistance rates of less than 20% were observed for nitroxoline (3.9%), fosfomycin (4.6%), nitrofurantoin (11.7%), cefuroxime (13.5%) and ciprofloxacin (14.2%). Resistance to trimethoprim/sulfamethoxazole (SXT) (20.1%), amoxicillin-clavulanic acid (20.5%), trimethoprim (24.2%), pivmecillinam (29.9%) and ampicillin (53.7%) was considerably higher. In the subgroup of outpatient women aged 15-50 years, resistance rates were generally lower. Resistance rates of all antibiotics decreased from 2016 to 2021. Multiple logistic regression revealed the lowest adjusted odds ratio (ORadj) of 0.838 (95% confidence interval (CI): 0.819-0.858; p < 0.001) for pivmecillinam and the highest ORadj of 0.989 (95% CI: 0.972-1.007; p = 0.226) for nitrofurantoin.ConclusionsResistance has generally decreased over the past years, independent of sex, age and causative pathogen. Our data provide an important basis for empirical antibiotic recommendations in various settings and patient collectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.